Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/105354
Title: C.E.R.A administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II
Other Titles: C.E.R.A. en administración mensual corrige y mantiene niveles estables de hemoglobina en pacientes con enfermedad renal crónica no en diálisis: estudio observacional MICENAS II
Author: Martínez Castelao, Alberto
Cases Amenós, A. (Aleix)
Coll, Elisabet
Bonal, Jordi
Galcerán, Josep M.
Fort, Joan
Moreso, Francesc
Torregrosa Prats, José Vicente
Guirado, Lluís
Ruiz, Pilar
Investigators of the Micena II Study
Keywords: Anèmia
Malalties del ronyó
Eritropoesi
Assaigs clínics
Insuficiència renal crònica
Eritropoetina
Anemia
Kidney diseases
Erythropoiesis
Clinical trials
Chronic renal failure
Erythropoietin
Issue Date: 22-Oct-2014
Publisher: Elsevier España
Abstract: BACKGROUND AND OBJECTIVE: C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in once-monthly administration in chronic kidney disease (CKD) patients. The aim of this study was to evaluate the management of anemia with C.E.R.A. in CKD patients not on dialysis in the clinical setting. METHODS: Two hundred seventy two anemic CKD patients not on dialysis treated with C.E.R.A. were included in this retrospective, observational, multicentric study during 2010. Demographical characteristics, analytical parameters concerning anemia, treatment data and iron status were recorded. RESULTS: C.E.R.A. achieved a good control of anemia in both naïve patients (mean Hemoglobin 11.6g/dL) and patients converted from a previous ESA (mean Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. once monthly during the correction phase and required a low monthly dose (median dose 75 µg/month). The same median dose was required in patients converted from a previous ESA, and it was lower than recommended in the Summary of Product Characteristics (SPC). Iron status was adequate in 75% of anemic CKD patients, but only 50% of anemic patients with iron deficiency received iron supplementation. CONCLUSIONS: C.E.R.A. corrects and maintains stable hemoglobin levels in anemic CKD patients not on dialysis, requiring conversion doses lower than those recommended by the SPC, and achieving target hemoglobin levels with once-monthly dosing frequency both in naïve and converted patients.
Note: Reproducció del document publicat a: https://doi.org/10.3265/Nefrologia.pre2014
It is part of: Nefrología, 2014, vol. 35, num. 1, p. 80-86
Related resource: https://doi.org/10.3265/Nefrologia.pre2014
URI: http://hdl.handle.net/2445/105354
ISSN: 0211-6995
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
653757.pdf689.28 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons